Washinton: U.S. pharmaceutical Pfizer and German biotech company BioNTech said they have started a late-stage human study of their coronavirus vaccine candidate.
In a statement on Monday, the companies said the trial will consist of up to 30,000 volunteers between the ages of 18 and 85 across 120 locations worldwide where there is significant transmission of COVID-19.
Those in the trial will receive a 30-microgram dose level of the vaccine in a two-dose regimen, it said.
“The initiation of the Phase 2/3 trial is a major step forward in our progress toward providing a potential vaccine to help fight the ongoing COVID-19 pandemic, and we look forward to generating additional data as the program progresses,” said Ugur Sahin, CEO and co-founder of BioNtech. “Many steps have been taken toward this important milestone and we would like to thank all those involved for their extraordinary commitment.”
